BSH 2024 | The safety & efficacy of emicizumab in patients under 18 months with hemophilia A
To prevent intracranial hemorrhage, factor VIII prophylaxis is critical in infants with hemophilia A. However, using a central access device for its administration is invasive and inconvenient for children and their families. Emicizumab, a bispecific monoclonal antibody, was approved in 2019 and provides an alternative for patients. Eman Hassan, MD, University Hospitals Birmingham, Birmingham, UK, discusses the safety and efficacy of emicizumab in previously untreated and minimally treated patients with hemophilia A under 18 months of age. The agent had not previously been investigated in this patient population; however, it was found to show encouraging safety and efficacy. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
